Identification of alternative mechanisms of resistance to FGFR inhibitor treatment in FGFR1-amplified large cell compared to FGFR1-amplified small cell lung cancer models

被引：1
|
作者：
Jovcheva, Eleonora [1 ]
Ogata, Souichi [1 ]
Van De Ven, Kelly [1 ]
Paulussen, Caroline [1 ]
Van de Weyer, Inez [1 ]
Wolf, Hans D. [1 ]
Ceulemans, Hugo [1 ]
McClue, Steve [2 ]
Vialard, Jorge [1 ]
Perera, Timothy [1 ]
机构：
[1] Janssen, Beerse, Belgium
[2] Janssen, High Wycombe, Bucks, England
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-LB-329
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
329
引用
收藏
页数：2
相关论文
共 50 条
  • [21] MAP-kinase pathway activation facilitates survival of persistent FGFR1-amplified lung cancer cells upon FGFR inhibition
    Malchers, Florian
    Ercanoglu, Meryem Seda
    Thomas, Roman Kurt
    CANCER RESEARCH, 2016, 76
  • [22] Paradoxical cancer cell proliferation after FGFR inhibition through decreased p21 signaling in FGFR1-amplified breast cancer cells
    Chi, Feng
    Griffiths, Jason I.
    Nath, Aritro
    Bild, Andrea H.
    BREAST CANCER RESEARCH, 2024, 26 (01)
  • [23] Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer
    Golfmann, Kristina
    Meder, Lydia
    Koker, Mirjam
    Volz, Caroline
    Borchmann, Sven
    Tharun, Lars
    Dietlein, Felix
    Malchers, Florian
    Florin, Alexandra
    Buettner, Reinhard
    Rosen, Neal
    Rodrik-Outmezguine, Vanessa
    Hallek, Michael
    Ullrich, Roland T.
    ONCOGENE, 2018, 37 (42) : 5682 - 5693
  • [24] Correction: FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial–mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
    Kaixuan Wang
    Wenxiang Ji
    Yongfeng Yu
    Ziming Li
    Xiaomin Niu
    Weiliang Xia
    Shun Lu
    Oncogene, 2020, 39 : 6619 - 6620
  • [25] Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer
    Kristina Golfmann
    Lydia Meder
    Mirjam Koker
    Caroline Volz
    Sven Borchmann
    Lars Tharun
    Felix Dietlein
    Florian Malchers
    Alexandra Florin
    Reinhard Büttner
    Neal Rosen
    Vanessa Rodrik-Outmezguine
    Michael Hallek
    Roland T. Ullrich
    Oncogene, 2018, 37 : 5682 - 5693
  • [26] FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer
    Servetto, Alberto
    Kollipara, Rahul
    Formisano, Luigi
    Lin, Chang-Ching
    Lee, Kyung-min
    Sudhan, Dhivya R.
    Hanker, Ariella B.
    Chatterjee, Sumanta
    Guerrero-Zotano, Angel
    Gonzalez-Ericsson, Paula
    Mendiratta, Saurabh
    Akamatsu, Hiroaki
    James, Nicholas
    Kittler, Ralf
    Arteaga, Carlos L.
    CANCER RESEARCH, 2021, 81 (04)
  • [27] Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression
    Kotani, H.
    Ebi, H.
    Kitai, H.
    Nanjo, S.
    Kita, K.
    Huynh, T. G.
    Ooi, A.
    Faber, A. C.
    Mino-Kenudson, M.
    Yano, S.
    ONCOGENE, 2016, 35 (27) : 3587 - 3597
  • [28] Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH
    Russell, Prudence A.
    Yu, Yong
    Young, Richard J.
    Conron, Matthew
    Wainer, Zoe
    Alam, Naveed
    Solomon, Benjamin
    Wright, Gavin M.
    MODERN PATHOLOGY, 2014, 27 (12) : 1621 - 1631
  • [29] CRISPR-Mediated Kinome Editing Prioritizes a Synergistic Combination Therapy for FGFR1-Amplified Lung Cancer
    Yang, Zhang
    Liang, Shun-Qing
    Yang, Haitang
    Xu, Duo
    Bruggmann, Remy
    Gao, Yanyun
    Deng, Haibin
    Berezowska, Sabina
    Hall, Sean R. R.
    Marti, Thomas M.
    Kocher, Gregor J.
    Zhou, Qinghua
    Schmid, Ralph A.
    Peng, Ren-Wang
    CANCER RESEARCH, 2021, 81 (11) : 3121 - 3133
  • [30] FGFR1-ERK1/2-SOX2 axis promotes cell proliferation, epithelial-mesenchymal transition, and metastasis in FGFR1-amplified lung cancer
    Wang, Kaixuan
    Ji, Wenxiang
    Yu, Yongfeng
    Li, Ziming
    Niu, Xiaomin
    Xia, Weiliang
    Lu, Shun
    ONCOGENE, 2018, 37 (39) : 5340 - 5354
12345